716
Participants
Start Date
December 31, 2011
Primary Completion Date
November 30, 2015
Study Completion Date
November 30, 2015
onabotulinumtoxinA
Participants received 155 U of onabotulinumtoxinA approximately every 12 weeks for 108 weeks. OnabotulinumtoxinA was administered as 31 intramuscular injections in 7 head/neck muscle areas.
Montefiore Medical Center, The Bronx
Dent Neurologic Institute, Amherst
Jefferson University Hospitals, Philadelphia
Kaiser Permanente Research Office/Neurology Department, Largo
Mid-Atlantic Headache Institute, Baltimore
Headache Wellness Center, Greensboro
Premiere Research Institute at Palm Beach Neurology, West Palm Beach
Tampa General Hospital, Tampa
Wesley Headache Clinic, Cordova
Ohio Clinical Research Partners, LLC, Canton
Robbins Headache Clinic, Northbrook
Mercy Health Research, St Louis
Baylor Research Institute, Dallas
Advanced Neurosciences Research, LLC, Fort Collins
Renown Institute for Neurosciences, Reno
USC Neurology, Los Angeles
Neurological Research Institute, Santa Monica
The Research Center of Southern California, LLC, Encinitas
UCSF Headache Center, San Francisco
Arizona Neurological Institute, Scottsdale
Clinvest Research, Springfield
Dr. Joseph Frasca, Adelaide
Dr. Con Yiannikas, Burwood
Associate Professor Richard Stark, Melbourne
Richmmond Neurology, Richmond
Associate Professor John O'Sullivan, Spring Hill
Hallym University Sacred Heart Hospital, Dongan-gu, Anyang
Uijeongbu St. Mary's Hospital, Uijeongbu-si
Kangbuk Samsung Hospital, Jongno-Gu
Seoul St. Mary's Hospital, Jongno-Gu
Seoul Eulji Hospital, Nowon-Gu
Yonsei University Dental Hospital, Seodaemum-Gu
Lead Sponsor
Allergan
INDUSTRY